The management of transaminitis in patients receiving idelalisib VJHemOnc – Video Journal of Hematology & HemOnc 1:24 8 years ago 2 493 Далее Скачать
The risk of infection for CLL patients receiving idelalisib VJHemOnc – Video Journal of Hematology & HemOnc 2:41 8 years ago 290 Далее Скачать
Dr. Jeffrey Jones on Idelalisib and Ibrutinib in Patients With CLL Targeted Oncology 2:14 8 years ago 275 Далее Скачать
Dr. Zelenetz on Treatment for Patients With CLL Who Fail on Ibrutinib or Idelalisib OncLive 1:33 7 years ago 340 Далее Скачать
Side effects of idelalisib in CLL and how to manage them VJHemOnc – Video Journal of Hematology & HemOnc 1:57 8 years ago 141 Далее Скачать
Podcast 767: Transaminitis and Rhabdomyolysis Emergency Medical Minute 3:02 2 years ago 312 Далее Скачать
Drug-Induced Liver Disease, Causes, Signs and Symptoms, Diagnosis and Treatment. Medical Centric 4:42 3 years ago 53 983 Далее Скачать
CLL: Long-term updates on ibrutinib and idelalisib HMP Education 25:09 6 years ago 2 193 Далее Скачать
Updated analysis of Phase III trial of idelalisib combined with bendamustine and rituximab in CLL VJHemOnc – Video Journal of Hematology & HemOnc 2:52 7 years ago 200 Далее Скачать
Dr. Wierda on Factors to Consider in Frontline Management of CLL OncLive 2:07 8 years ago 233 Далее Скачать
Results of Phase II trial to assess the efficacy and safety of idelalisib VJHemOnc – Video Journal of Hematology & HemOnc 4:04 8 years ago 61 Далее Скачать
Targeted therapies for CLL: new data and unanswered questions VJHemOnc – Video Journal of Hematology & HemOnc 3:18 8 years ago 355 Далее Скачать
Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib HMP Education 18:36 6 years ago 1 615 Далее Скачать
ASCO 2016 highlights for CLL VJHemOnc – Video Journal of Hematology & HemOnc 1:12 8 years ago 313 Далее Скачать
